GlassScriptPhysician profile
Ivy H Spears
NPI 1093797912
$1,183.88
in general payments reported to CMS, 2019-2025
11 companies · $190 in 2025
The $190 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $98.60 · 2021: $77.73 · 2022: $77.77 · 2023: $155 · 2024: $243 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583 · Education: $4.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.41 |
| Education | $4.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $394.38 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Johnson & Johnson Vision Care, INC. | $299.36 | 2019-2022 | |
| Abbvie INC. | $123.42 | 2023 | Xen Glaucoma Treatment System |
| Alcon Vision LLC | $80.59 | 2024 | Precision 1 |
| Johnson & Johnson Surgical Vision, INC. | $76.52 | 2019 | |
| Visioneering Technologies, INC. | $62.50 | 2019 | |
| Menicon America INC | $51.96 | 2019-2020 | |
| Abb Con-Cise Optical Group LLC | $37.06 | 2019-2020 | |
| Coopervision INC. | $31.42 | 2020-2023 | Biofinity Contact Lens |
| Thea Pharma INC. | $14.75 | 2025 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivy Spears listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.